drugset / Trial / NCT01111279
Clinical Safety and Tolerability Study of gpASIT+TM and gpASIT+TM/Immunoregulating Adjuvant to Treat Seasonal Grass Pollen Rhinoconjunctivitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess the safety and tolerability of gpASIT+TM administered subcutaneously in absence or in presence of an immunoregulating adjuvant in grass pollen allergic patients.
Timeline
- Start
- 2010-03
- Primary completion
- 2010-09
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DnaK | Unknown | — | Subcutaneous |
| Subject | gpASIT+TM | Unknown | — | Subcutaneous |